RE
Therapeutic Areas
Avacta Group Pipeline
| Drug | Indication | Phase |
|---|---|---|
| AVA6000 (faridoxorubicin) | Salivary Gland Cancer (SGC), Triple-Negative Breast Cancer (TNBC), Soft Tissue Sarcoma (STS) | Phase 1b |
| AVA6103 (FAP-Exd) | Pancreatic cancer, Gastric and Gastroesophageal Junction cancers, Cervical and Vulvar cancers, Small Cell Lung Cancer | Phase 1 |
| AVA6207 | Not disclosed (difficult to treat cancers) | Preclinical |
| AVA7100 | Not disclosed | Preclinical |
Leadership Team at Avacta Group
CR
Curtis Rink
Scientist (Presentation Author)
TC
Tom Clough
Scientist (Presentation Author)
EW
Ellen Watts
Scientist (Presentation Author)
FO
Folake Orafidiya
Scientist (Presentation Author)
MH
Marine Houée
Scientist (Presentation Author)
SB
Sophie Brown
Scientist (Presentation Author)
VJ
Victoria Juskaite
Scientist (Presentation Author)
GL
Gezim Lahu
Scientist (Presentation Author)
KC
Karen Campbell
Scientist (Presentation Author)
DL
Dave Liebowitz
Scientist (Presentation Author)